

Ophthalmic Drugs: Advancing Your Ocular Drug Pipeline

Have Your Say: Key Questions Answered this November

LONDON, UNITED KINGDOM, July 31, 2017 /EINPresswire.com/ -- Do you have questions on novel endpoints in clinical trials? Looking to explore long-term clinical gene expression in patients? Interested in receiving progressive insight into the future of chronic ocular diseases?

SMi Group are delighted to welcome your insights and have you join the discussions at Ophthalmic Drugs 2017, which is being held on the 28th – 29th

November 2017 at the Copthorne Tara Hotel in London, UK. Have your say and questions answered during our [two](#) pivotal sessions, presented by Oxford BioMedica and NightstaRx.

DAY 1: Development of a Lentiviral Vector Platform for the Treatment of Chronic Ocular Disease
Speaker: Scott Ellis, Head of Early Development, Oxford BioMedica.

This presentation will introduce the LentiVector® platform for gene and cell therapy, enable you to experience translating from preclinical studies to First-in-Man clinical trials and explore current challenges and future goals.

DAY 1: Novel Endpoints in Ophthalmic Clinical Trials
Speaker: Aniz Girach, Chief Medical Officer, NightstaRx.

Get stuck in with NightstaRx as they examine how you can measure each key endpoint in a certain timescale, explore the pros and cons of these and gain a deeper understanding by hearing from regulators as they provide their feedback on these endpoints.

Check out the full agenda here: www.opthalmicdrugs.com/pr2

For those looking to attend there is currently a £300 [early-bird](#) saving, for a limited time only.

Further information is available at: www.opthalmicdrugs.com/pr2

SMi is Proud to Present the Launch of...
Ophthalmic Drugs

Date: 28th – 29th November 2017

Location: London, UK



A Snap Shot of Our Industry Leading Companies Presenting this November

- Santen Inc
- Aerie Pharmaceuticals
- Novartis
- Bayer
- Boehringer Ingelheim
- Shire
- Envisia Therapeutics

CHECK OUT THE FULL SPEAKER LINE-UP!

#ophdrugs

Snapshot of 2017 Attendees

Website: <http://www.opthalmicdrugs.com/pr2>

Sponsors:

- EXPERIMENTICA
- LEICA MICROSYSTEMS

---end---

Contact Information:

For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Pav Solanki
SMi Group
2078276048
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.